Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1RN | P18510 | 1/20 | 0.54 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.54 |
| ▸ | NPY4R | P50391 | 11/20 | 0.54 |
| ▸ | NPY1R | P25929 | 8/20 | 0.54 |
| ▸ | NPY2R | P49146 | 6/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 2/20 | 0.51 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29728788 | 0.98 | OPRM1 (0.55) | IL1RNERAP2NPY4RNPY1RNPY2R | |
| SCHEMBL29375823 | 0.92 | IL1RN (0.55) | IL1RNERAP2NPY4RNPY1RNPY2R | |
| SCHEMBL2195747 | 0.92 | IL1RN (0.56) | IL1RNERAP2NPY4RNPY1RNPY2R | |
| SCHEMBL29373148 | 0.91 | BACE1 (0.60) | OPRM1OPRD1OPRK1BACE1BACE2 | |
| SCHEMBL30558097 | 0.90 | KISS1R (0.52) | NPY4RNPY1RNPY2RNPY5ROPRD1 | |
| SCHEMBL30124163 | 0.90 | IL1RN (0.52) | IL1RNERAP2NPY4RNPY1RNPY2R | |
| SCHEMBL30070212 | 0.89 | NPY4R (0.67) | NPY4RNPY1RNPY2ROPRM1OPRD1 | |
| SCHEMBL30124150 | 0.89 | NPY4R (0.58) | IL1RNERAP2NPY4RNPY1RNPY2R | |
| SCHEMBL29375830 | 0.88 | BACE1 (0.59) | OPRM1OPRD1OPRK1BACE1BACE2 | |
| SCHEMBL30473779 | 0.88 | NPY4R (0.60) | IL1RNERAP2NPY4RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117098843-A | Subtilisin variants and uses thereof | 费森尤斯卡比有限公司 | 2023-11-21 | — | — | CN | claimed |
| EP-3864032-B1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | FRESENIUS KABI IPSUM S R L (IT) | 2022-11-30 | — | — | EP | claimed |
| US-11396533-B2 | Process for the manufacture of GLP-1 analogues | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-07-26 | — | — | US | claimed |
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-02-10 | — | — | US | claimed |
| CN-119060201-A | Chemoenzymatic synthesis of liraglutide, soxhlet Ma Lutai and GLP-1 | 费森尤斯卡比有限公司 | 2024-12-03 | — | — | CN | disclosed |
| WO-2024231312-A2 | COMBINATION THERAPY | UNION therapeutics A/S (DK) | 2024-11-14 | — | — | WO | disclosed |
| WO-2024175930-A1 | COMPOUNDS | IP2IPO INNOVATIONS LIMITED (GB) | 2024-08-29 | — | — | WO | disclosed |
| CN-111819191-B | Chemoenzymatic synthesis of liraglutide, soxhlet Ma Lutai and GLP-1 | 费森尤斯卡比有限公司 | 2024-08-20 | — | — | CN | disclosed |
| CN-112912390-B | GLP-1 analogues and methods of preparation | 北京费森尤斯卡比医药有限公司 | 2023-12-15 | — | — | CN | disclosed |
| EP-4259646-A1 | NOVEL COMPOUNDS | IP2IPO Innovations Limited (GB) | 2023-10-18 | — | — | EP | disclosed |
| CN-116836258-A | Solid phase synthesis method of liraglutide | 辽宁药联制药有限公司 | 2023-10-03 | — | — | CN | disclosed |
| EP-4196495-A1 | EXENDIN-4 PEPTIDE ANALOGUES | TXP Pharma GmbH (CH) | 2023-06-21 | — | — | EP | disclosed |
| EP-3864032-B1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | FRESENIUS KABI IPSUM S R L (IT) | 2022-11-30 | — | — | EP | disclosed |
| US-11396533-B2 | Process for the manufacture of GLP-1 analogues | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-07-26 | — | — | US | disclosed |
| WO-2022123271-A1 | NOVEL COMPOUNDS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022034062-A1 | EXENDIN-4 PEPTIDE ANALOGUES | TXP PHARMA AG (CH) | 2022-02-17 | — | — | WO | disclosed |
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | GLP1R, IAPP, VIP | IL1RN 840/4885ERAP2 1697/4885NPY4R 8/4885 |
| US-11396533-B2 | Process for the manufacture of GLP-1 analogues | GLP1R, IAPP, VIP | IL1RN 840/4885ERAP2 1697/4885NPY4R 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.